Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer

被引:63
作者
Caudle, A. S. [1 ]
Kim, H. J. [1 ]
Tepper, J. E. [2 ]
O'Neil, B. H. [3 ]
Lange, L. A. [4 ]
Goldberg, R. M. [3 ]
Bernard, S. A. [3 ]
Calvo, B. F. [1 ]
Meyers, M. O. [1 ]
机构
[1] Univ N Carolina, Div Surg Oncol, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC USA
[3] UNC Sch Med, Dept Med Oncol, Chapel Hill, NC USA
[4] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
关键词
rectal cancer; chemotherapy; radiation therapy; diabetes;
D O I
10.1245/s10434-008-9873-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Although diabetic patients with rectal cancer have poorer outcomes than their nondiabetic counterparts, few studies have looked at diabetics' response to therapy as an explanation for this disparity. This study compares the neoadjuvant chemoradiotherapy (CRT) response in diabetic and nondiabetic patients with locally advanced rectal cancers. Methods: This is a single-institution, retrospective review of rectal cancer patients who received CRT followed by resection from 1995 to 2006. Pretreatment tumor-node-metastasis (TNM) staging was determined using endorectal ultrasound, computed tomography (CT) scan, and magnetic resonance imaging (MRI); post-treatment staging was determined by pathological review. Results: 110 patients were included; seventeen had diabetes and 93 were nondiabetics. Pretreatment staging was similar in both groups. Sixteen of the diabetics (94%) completed CRT compared to 92% (86/93) of the nondiabetics. Tumor downstaging rates were similar in the two groups (53% in diabetics, 52% in nondiabetics). Nondiabetic patients had a higher rate of nodal downstaging although not statistically significant (67% versus 27%, P = 0.80). While none of the diabetics patients achieved a pathologic complete response (pCR), 23% (21/93) of the nondiabetics did (P = 0.039). Local progression rates were higher in the diabetic group (24% versus 5%, P = 0.046). Conclusion: Our study shows that neoadjuvant chemoradiotherapy in rectal cancer is less effective in diabetic patients than in nondiabetics. While minimal differences are found in the rate of downstaging, the rate of achieving a complete pathologic response was significantly higher in nondiabetic patients, and in fact was not seen in any of our diabetic patients. This may explain the poorer outcomes seen in diabetic patients with rectal cancer.
引用
收藏
页码:1931 / 1936
页数:6
相关论文
共 25 条
[1]   Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy [J].
Chan, AKP ;
Wong, A ;
Jenken, D ;
Heine, J ;
Buie, D ;
Johnson, D .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (03) :665-677
[2]   2005 presidential address: Diabetes: Past, present, and future [J].
Cherrington, Alan D. .
DIABETES CARE, 2006, 29 (09) :2158-2164
[3]   Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults [J].
Coughlin, SS ;
Calle, EE ;
Teras, LR ;
Petrelli, J ;
Thun, MJ .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 159 (12) :1160-1167
[4]   Impairment of anorectal function in diabetes mellitus parallels duration of disease [J].
Epanomeritakis, E ;
Koutsoumbi, P ;
Tsiaoussis, I ;
Ganotakis, E ;
Vlata, M ;
Vassilakis, JS ;
Xynos, E .
DISEASES OF THE COLON & RECTUM, 1999, 42 (11) :1394-1400
[5]   A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision [J].
García-Aguilar, J ;
de Anda, EH ;
Sirivongs, P ;
Lee, SH ;
Madoff, RD ;
Rothenberger, DA .
DISEASES OF THE COLON & RECTUM, 2003, 46 (03) :298-304
[6]   Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women [J].
Hu, FB ;
Manson, JE ;
Liu, SM ;
Hunter, D ;
Colditz, GA ;
Michels, KB ;
Speizer, FE ;
Giovannucci, E .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (06) :542-547
[7]   Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response [J].
Jones, Robin L. ;
Smith, Ian E. .
LANCET ONCOLOGY, 2006, 7 (10) :869-874
[8]  
Jordan BF, 2002, CANCER RES, V62, P3555
[9]   Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women [J].
Kaaks, R ;
Toniolo, P ;
Akhmedkhanov, A ;
Lukanova, A ;
Biessy, C ;
Dechaud, H ;
Rinaldi, S ;
Zeleniuch-Jacquotte, A ;
Shore, RE ;
Riboli, E .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (19) :1592-1600
[10]   Insulin resistance, apoptosis, and colorectal adenoma risk [J].
Keku, TO ;
Lund, PK ;
Galanko, J ;
Simmons, JG ;
Woosley, JT ;
Sandler, RS .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (09) :2076-2081